Your donation will make a difference:
Cystic Fibrosis Trust

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at

Please Log in

Log in

Not a registered user? Register with us

This trial will be added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

26-29 of 29 results for all trials

Sort by:

Filter by

Trial status

Inclusion age


Study design



Therapeutic category

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis (CF) is a genetic disease caused by mutations in the gene encoding a cell transport protein (ion channel). This ion channel transports chloride ions in and out of cells in multiple organ systems. When ions are not transported correctly the salt and water balance in cells and tissues is not controlled, leading to the production of sticky mucus in the lungs, airways and intestines. Vertex is developing treatments to help increasing production of the ion channel and increase transport of chloride ions. IVA and Orkambi are two drugs that have been approved for treatment. Vertex is also developing TEZ and now VX-440. VX-440 increases the production of the ion channel, but in a different way to the current treatments. So, it is hoped that by using VX-440 as well as current treatments the production of the ion channel will be increased even further. Primary Objectives 1) To evaluate the safety and tolerability of VX-440 in dual and triple combination with tezacaftor (TEZ) and/or ivacaftor (IVA). 2) To evaluate to effectiveness of VX-440 in dual and triple combination with TEZ and/or IVA

Phase II
  • Age

    13 - 17

  • Length of participation

    20 weeks

  • Trial status


  • Therapeutic category

    Restore CFTR Function

Study of CTX 4430 in Cystic Fibrosis Patients

The purpose of this study is to assess the safety and tolerability of multiple oral doses of CTX-4430 when administered to cystic fibrosis (CF) patients once-daily (QD) for 15 days. This study will include two dose levels. For each dose level, blood samples will be collected for exploratory PK and PD assay validation. In addition, sputum will be collected for exploratory biomarker analysis. Following multiple dose administration, pulmonary function and exploratory lung clearance index (LCI) measurements will be taken.

Phase II/III
  • Age


  • Length of participation

    55 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category


Evaluation of the High Frequency Digit Triplet test in Cystic Fibrosis

The purpose of this study is to find out whether the High Frequency Digit Triplet test can be used to screen patients with cystic fibrosis for hearing loss in conditions of health and pulmonary exacerbation. It is also designed to find out the youngest age at which a child can perform the test, the prevalence of hearing loss in a CF population and the prevalence of genetic mutations known to be associated with hearing loss in the same population

Not Applicable
  • Length of participation

    1 day

  • Trial status


  • Therapeutic category


Vertex VX14-661-106 Cystic Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Phase III
  • Trial status


26-29 of 29 results for all trials